A new 3D-printed, all-liquid device automates complex chemical reactions on demand – enabling drug screening with limited materials, such as patient biopsies, says researcher.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
Zenith-Cognizant Technologies emerges from an acquisition aimed to streamline solutions as more complex “smart factories” become a greater focus in the biopharmaceutical industry.
Dassault Systèmes is set to acquire Medidata in an all-cash transaction valued at $5.8bn – a deal which will combine the power of modeling and simulation with data science to “catalyze the next generation of patient-inclusive therapeutics,” says CEO.
As the cell and gene therapies market evolves, CDMOs and pharmaceutical companies aim to adapt to the rising demands and serve larger patient populations.
Covance seeks an Economic Revitalization Area designation at its Indianapolis, IN-based site, at which the company looks to expand its sample storage capacity and add space “dedicated to innovation" as part of an $11.8m construction project.
Atomwise signs a multi-year agreement with Eli Lilly and Company through which it will apply its patented artificial intelligence technology to support Lilly’s preclinical drug discovery efforts.
Gilead and HitGen have signed a drug discovery collaboration – one of several recently announced agreements as HitGen sees increased demand for its technology, says CSO.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
